🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧪 Collaborators report on a 45-year-old woman with treatment-refractory Jo-1-associated anti-synthetase syndrome, who initially achieved disease remission after CD19-CAR T-cell therapy but then experienced disease relapse after 9 months. Nature Medicine |

In a recent Phase I trial, investigators from Zhejiang University showed that CD19-BBz CAR-NK cells were feasible and therapeutically safe, capable of inducing durable response in patients with B cell #lymphoma. 🩺 Nature Cancer | go.nature.com/4jJlVrE

Scientists from Universitätsmedizin Frankfurt provide a comprehensive summary of the current status of #GeneTherapy approaches, highlighting advantages, limitations, and potential future developments. ✅ Check out their review in Molecular Therapy! bit.ly/4lFW7yg

Researchers introduced an AAV-reporter-based in vivo transcriptional enhancer reconstruction (ARBITER) workflow. With ARBITER, they showed that the conserved non-coding elements within the gene locus collaboratively regulate the expression of Slc26a5. 🧬 bit.ly/3RuaAzv

🧪 Researchers led by Dr. Anna Kajaste-Rudnitski identified innate immune mechanisms of vector sensing in the CNS that can potentially contribute to #AAV-associated #neurotoxicity. Nature Communications | go.nature.com/3S38pmE

🧬 Join leading minds in #CancerResearch at the upcoming Frontiers in Cancer Immunotherapy Symposium hosted by NYAS this June. Conference topics include RNA Technologies, Engineered Cell Therapy, and more! 🔗 Register now: bit.ly/42uoWq3 #Immunotherapy

This Trends in Biotechnology review explores human herpesviruses 6 and 7 reactivations in CAR-T cell therapy and discusses mitigation strategies during allogeneic CAR-T cell manufacturing. 📖 Learn more: bit.ly/4jJKgNW

Researchers, including Drs. Jan Frenking and Marc S. Raab from Universitätsklinikum Heidelberg, highlight that bridging intensity distinctly shapes the trajectory of #hematopoietic recovery after B-cell maturation antigen CAR-T. 📚 More in Blood Advances: bit.ly/4jT2Kvu

Researchers led by Dr. Douglas Gould introduced a versatile mouse model carrying a multifunctional dual-color fluorescence-tagged allele with knockout potential for the fundamental basement membrane component type IV collagen alpha 1. 🔗 bit.ly/3YUsLCm

Enjoy reading reviews? Check out this one on chimeric brain models! Peng Jiang Lab highlight recent advancements in using chimeric models to study human neural development, aging, and disease. 💡 Learn more: bit.ly/3RDWRX0

In this Cancer Discovery review, Dr. Nicholas Vitanza and colleagues discuss the current state of the pediatric CNS CAR T-cell field through the lens of translational obstacles to broader clinical success. Learn more: bit.ly/4lSyDGt

.Simon Heidegger, MD's team showed that insufficient activity of the innate RNA-sensing receptor system, RIG I/MAVS, leads to tumor cell-inherent resistance to CAR T cell attack. 📕 Read more in Cancer Research: bit.ly/4iOv951

Are you attending ISCT this week? 😀 Make sure to check out the Translation to Clinic plenary session chaired by Dr. Alice Bertaina! This session will focus on next-generation cell therapies for #autoimmunity. bit.ly/42TSDj1

Hear from experts at Adicet Bio, Caribou Bioscience, IN8Bio, and more at the 7th Annual Allogeneic Cell Therapies Summit to uncover the latest innovations, strategies, and advancements for a smoother journey to the clinic and beyond! Use code '55688StemCell10' for 10% off

New in PNASNews! Researchers led by Dr. Carl June suggest that employing Cas9 nickase–based adenine-base editing mitigates the genotoxicity associated with nuclease-active Cas9, potentially leading to superior cell therapies. 👉 bit.ly/4m1CjFK

New in NEJM! Collaborators including Carl June assessed the safety, feasibility, and preliminary efficacy of huCART19-IL18 in patients with relapsed or refractory #lymphoma after previous anti-CD19 CAR T-cell therapy. 🔎 Discover their findings: bit.ly/3YD2PeG

🧬 Join leading minds in #CancerResearch at the upcoming Frontiers in Cancer Immunotherapy Symposium hosted by NYAS this June. Conference topics include RNA Technologies, Engineered Cell Therapy, and more! 🔗 Register now: bit.ly/42uoWq3 #Immunotherapy

A research team from Memorial Sloan Kettering Cancer Center systematically compared the efficiency of various CRISPRa systems and identified the synergistic activation mediator system as the most potent for activating silent genes in hPSCs. 🧫🧬🤫 bit.ly/4df7wBy

Researchers led by Dr. Michelle Monje🎗️ 🟦 demonstrated in mouse models that CAR T cell therapy for both CNS and non-CNS cancers impaired cognitive function and induced a persistent CNS immune response. 🧫 Cell | bit.ly/3H3RbTU